On October 24, 2025, WuXi AppTec Co., Ltd. (Stock Code: 2359) announced that its wholly-owned subsidiary, WuXi AppTec (Shanghai) Co., Ltd., entered into a sale and purchase agreement with Hillhouse Investment Management to sell all shares of WuXi Clinical Development Services (Shanghai) Co., Ltd. and WuXi MedKey Med-Tech Development (Shanghai) Co., Ltd. The transaction’s objective is to strengthen WuXi AppTec’s core CRDMO services, involving drug discovery, laboratory testing, process development, and manufacturing.

According to the announcement, WuXi Clinical and WuXi MedKey generated combined revenue of approximately RMB1.16 billion from January to September 2025, accounting for about 3.5% of WuXi AppTec’s unaudited revenue during that period. Their combined net profit was approximately RMB0.09 billion, representing about 0.7% of the company’s unaudited net profit for the same interval. The transaction does not constitute a connected or notifiable transaction under relevant listing rules, and completion is subject to conditions precedent and necessary regulatory approvals. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.